MAPK3 and melanoma: In fact,high ERK1/2 phosphorylation levels have been detected in clinical melanomametastases and various melanoma cell lines [47], and combination of BRAF and mitogen-activated proteinkinase inhibition is the elective treatment in patients with advanced BRAF-mutantmelanoma.